NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Price, News & Analysis $44.39 -0.51 (-1.14%) Closing price 04:00 PM EasternExtended Trading$44.65 +0.26 (+0.59%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ionis Pharmaceuticals Stock (NASDAQ:IONS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ionis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$44.04▼$45.8450-Day Range$42.38▼$63.5752-Week Range$42.08▼$86.74Volume1.81 million shsAverage Volume2.66 million shsMarket Capitalization$7.38 billionP/E RatioN/ADividend YieldN/APrice Target$89.48Consensus RatingModerate Buy Company Overview Ionis Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing medicines using antisense technology. Its platform is designed to selectively target RNA and regulate the production of disease-related proteins. The company develops therapies for neurological, cardiovascular and metabolic, and rare diseases. Ionis has developed and commercialized medicines both independently and through collaborations with larger pharmaceutical companies. Its marketed or partnered products include Spinraza (nusinersen) for spinal muscular atrophy, Tegsedi (inotersen) and Wainua (eplontersen) for hereditary transthyretin amyloidosis, and Tryngolza (olezarsen) for familial chylomicronemia syndrome. The company also maintains a pipeline of investigational antisense medicines, including candidates for neurological and cardiometabolic conditions. Founded in 1989, Ionis is headquartered in Carlsbad, California, and serves patients internationally through its own commercial activities and partnerships. The company has collaborated with organizations including Biogen and AstraZeneca. Brett P. Monia serves as chief executive officer and has held senior leadership roles at Ionis for many years.AI Generated. May Contain Errors. Read More Ionis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreIONS MarketRank™: 4.039453326455 of 5 starsIonis Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 68th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingIonis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 19 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialIonis Pharmaceuticals has a consensus price target of $89.48, representing about 98.7% upside from its current price of $45.03.Amount of Analyst CoverageIonis Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ionis Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($3.62) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -13.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 14.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Ionis Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.66% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 7.65.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently decreased by 8.24%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentIonis Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ionis Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 15 people have searched for IONS on MarketBeat in the last 30 days. This is a decrease of -12% compared to the previous 30 days.MarketBeat Follows5 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $997,309.00 in company stock, which represents 0.0133% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have bought 1,624.52% more of their company's stock than they have sold. Specifically, they have bought $1,058,700.00 in company stock and sold $61,391.00 in company stock.Percentage Held by Insiders1.81% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ionis Pharmaceuticals' insider trading history. Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IONS Stock News HeadlinesBMO Capital upgrades Ionis Pharmaceuticals to outperform from market performOctober 26 at 7:39 AM | msn.comIonis Pharmaceuticals: Compelling Long-Term Commercial UpsideOctober 25, 2026 | seekingalpha.comxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again until age 85. In 2008, one bad year wiped out more than half the savings of those aged 56 to 65. Today, the national debt stands at 38.86 trillion dollars, far higher than in 1929. See where your retirement stands with a free Retirement Protection Kit.October 29 at 1:00 AM | USA Capital Gold (Ad)Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Has Average Target Price of $89.14October 25, 2026 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by BMO Capital MarketsOctober 24, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Integra Lifesciences (IART) and vTv Therapeutics (VTVT)October 23, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Unicycive Therapeutics (UNCY)October 22, 2026 | theglobeandmail.comIonis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 1,357 Shares of StockOctober 20, 2026 | insidertrades.comSee More Headlines IONS Stock Analysis - Frequently Asked Questions How have IONS shares performed this year? Ionis Pharmaceuticals' stock was trading at $79.11 at the beginning of the year. Since then, IONS stock has decreased by 43.1% and is now trading at $45.0270. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, April, 29th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.29. The firm's quarterly revenue was up 86.4% compared to the same quarter last year. Read the conference call transcript. Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' top institutional shareholders include Pinnacle Associates Ltd. (0.26%), China Universal Asset Management Co. Ltd., Motley Fool Asset Management LLC and Sumitomo Mitsui Trust Group Inc. (0.04%). Insiders that own company stock include Brett P Monia, Spencer R Berthelsen, Elizabeth L Hougen, Eugene Schneider, C Frank Bennett, Brian Birchler, Patrick R O'neil, Richard S Geary, B Lynne Parshall, Joseph H Wender, Onaiza Cadoret-Manier, Michael R Hayden, Kyle Jenne, Holly B Kordasiewicz, Joseph Baroldi, Shannon L Devers, Joseph Klein III, Allene M Diaz and Eric Swayze. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ionis Pharmaceuticals investors own include Bristol Myers Squibb (BMY), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Alibaba Group (BABA). Company Calendar Last Earnings4/29/2026Today10/29/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IONS's financial health is in the Red zone, according to TradeSmith. IONS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IONS CIK874015 Webwww.ionis.com Phone(760) 931-9200Fax760-603-2700Employees1,402Year Founded1989Price Target and Rating Average Price Target for Ionis Pharmaceuticals$89.48 High Price Target$129.00 Low Price Target$56.00 Potential Upside/Downside+100.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage23 Analysts Profitability EPS (Trailing Twelve Months)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$381.39 million Net Margins-64.76% Pretax Margin-64.30% Return on Equity-111.08% Return on Assets-17.41% Debt Debt-to-Equity Ratio3.07 Current Ratio7.89 Quick Ratio7.73 Sales & Book Value Annual Sales$874.09 million Price / Sales8.47 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book14.75Miscellaneous Outstanding Shares166,184,000Free Float163,176,000Market Cap$7.40 billion OptionableOptionable Beta0.38 Social Links The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NASDAQ:IONS) was last updated on 10/29/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe "velvet rope" stock setups hiding from regular indicatorsK.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...The TradingPub | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's ...Decentralized Masters | SponsoredxIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't whole again un...USA Capital Gold | SponsoredA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
